<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2007-4085</journal-id>
<journal-title><![CDATA[Revista mexicana de urología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. mex. urol.]]></abbrev-journal-title>
<issn>2007-4085</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Mexicana de Urología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2007-40852022000200002</article-id>
<article-id pub-id-type="doi">10.48193/revistamexicanadeurologa.v82i2.763</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Tiempo al PSA nadir como un factor de respuesta en pacientes con CPRC metastásico tratados con abiraterona]]></article-title>
<article-title xml:lang="en"><![CDATA[Time to PSA nadir as a response factor in CPRC patients treated with abiraterone]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez-Martínez]]></surname>
<given-names><![CDATA[Néstor]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bautista-Vidal]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Morales-Jiménez]]></surname>
<given-names><![CDATA[Pedro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Galisteo]]></surname>
<given-names><![CDATA[Emilio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Regional Universitario Carlos Haya  ]]></institution>
<addr-line><![CDATA[ Málaga]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2022</year>
</pub-date>
<volume>82</volume>
<numero>2</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2007-40852022000200002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2007-40852022000200002&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2007-40852022000200002&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Objetivo:  Objetivar si el tiempo a conseguir un PSA nadir se relaciona con retraso en la progresión de la enfermedad.  Material y métodos: Estudio retrospectivo de 36 pacientes tratados con acetato de abiraterona en nuestro centro entre enero de 2014 y mayo de 2018 en fase de resistencia a la castración (CPRC) M1. Evaluamos los niveles de PSA al inicio del tratamiento, después de 4, 8 y 12 semanas, así como en los periodos sucesivos según nuestro protocolo. La respuesta de PSA se define como una disminución de &#8805;30% desde el inicio del tratamiento y la progresión de PSA como un aumento de &#8805;25% desde el inicio. Se considera progresión que suponga retirada de tratamiento aquella que asocie al menos dos de los siguientes criterios: progresión de PSA, progresión clínica y progresión radiológica. Hemos realizado un análisis de regresión lineal para las variables PSA al diagnóstico, PSA nadir, tiempo al nadir, PSA doubling time y descenso de al menos un 30% del nadir.  Resultados: En nuestra serie, el tiempo al nadir en la regresión lineal se asocia de manera positiva con la progresión, obteniendo mejores supervivencias libres de progresión cuando se consigue un PSA nadir a más largo plazo (p&lt;0.018); de manera que por cada mes de retraso en alcanzar el nadir se espera una progresión 0.8 meses más tardía.  Conclusiones: En nuestra serie alcanzar un PSA nadir más tardíamente se relaciona con una mejora en la supervivencia libre de progresión.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Objective: To determine if the time to achieve a PSA nadir is related to a delay in the progression of the disease.  Material and methods: A retrospective study of 36 patients treated with abiraterone acetate in our facilities between January 2014 and May 2018 in CPRC M1 phase. PSA levels are evaluated at the beginning of the treatment, after 4, 8 and 12 weeks, as well as in the successive periods according to our protocol. PSA response is defined as a decrease of &#8805;30% from the start of treatment and PSA progression as an increase of &#8805;25% from the beginning. It is considered as 'progression that supposes withdrawal of treatment' the one that associates at least two of the following criteria: PSA progression, clinical progression and radiological progression. We performed a linear regression analysis for PSA variables at diagnosis, PSA nadir, time at nadir, PSA doubling time and decrease of at least 30% of the nadir.  Results: In our series, time to nadir in linear regression is positively associated with progression, obtaining better progression-free survival when a longer-term nadir PSA is achieved (p &lt;0.018); so that for every month of delay in reaching the nadir, a 0.8 months belated progression is expected.  Conclusion: In our series, achieving a belated PSA nadir is related to an improvement in progression-free survival.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Prostate]]></kwd>
<kwd lng="en"><![CDATA[prostate-specific antigen]]></kwd>
<kwd lng="en"><![CDATA[castration]]></kwd>
<kwd lng="es"><![CDATA[Próstata]]></kwd>
<kwd lng="es"><![CDATA[antígeno prostático específico]]></kwd>
<kwd lng="es"><![CDATA[castración]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>INE</collab>
<source><![CDATA[Distribución de la mortalidad por causas (lista reducida), sexo y edad. Defunciones según la causa de muerte (2016)]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hussain]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tangen]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Higano]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Schelhammer]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
<name>
<surname><![CDATA[Faulkner]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162)]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2006</year>
<volume>24</volume>
<numero>24</numero>
<issue>24</issue>
<page-range>3984-90</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[K-J]]></given-names>
</name>
<name>
<surname><![CDATA[Pei]]></surname>
<given-names><![CDATA[X-Q]]></given-names>
</name>
<name>
<surname><![CDATA[Tian]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[D-P]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[J-H]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[Y-M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China]]></article-title>
<source><![CDATA[Asian J Androl]]></source>
<year>2018</year>
<volume>20</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>173-7</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Taussky]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bedwani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Meissner]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Bahary]]></surname>
<given-names><![CDATA[J-P]]></given-names>
</name>
<name>
<surname><![CDATA[Lambert]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Barkati]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comparison of early prostate-specific antigen decline between prostate brachytherapy and different fractionation of external beam radiation-Impact on biochemical failure]]></article-title>
<source><![CDATA[Brachytherapy]]></source>
<year>2018</year>
<volume>17</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>277-82</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Choueiri]]></surname>
<given-names><![CDATA[TK]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[D&#8217;Amico]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Ross]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Pomerantz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2009</year>
<volume>115</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>981-7</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thoma]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Validating early PSA response to enable improved treatment decisions]]></article-title>
<source><![CDATA[Nat Rev Urol]]></source>
<year>2016</year>
<volume>13</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>239</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rescigno]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lorente]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bianchini]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ferraldeschi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kolinsky]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Sideris]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate]]></article-title>
<source><![CDATA[Cancer. Eur Urol]]></source>
<year>2016</year>
<volume>70</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>724-31</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[SI]]></given-names>
</name>
<name>
<surname><![CDATA[Ahn]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[SJ.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate-specific antigen nadir and time to prostate-specific antigen nadir following maximal androgen blockade independently predict prognosis in patients with metastatic prostate cancer]]></article-title>
<source><![CDATA[Korean J Urol]]></source>
<year>2012</year>
<volume>53</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>607-13</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sasaki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Onishi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hoshina]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis]]></article-title>
<source><![CDATA[Prostate Cancer Prostatic Dis]]></source>
<year>2011</year>
<volume>14</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>248-52</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tomioka]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Yoshikawa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Miyake]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Anai]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chihara]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer]]></article-title>
<source><![CDATA[BMC Urol]]></source>
<year>2014</year>
<volume>14</volume>
<page-range>33</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
